Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 25, 2013
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 25, 2013

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/25/13 - Agnitio's Leading Pull Marketing Software Suite Chosen by Allergan
This scalable technology has allowed Allergan to achieve our initial goals across multiple countries in a short period of time, "says Gary Duncan, Head Of Digital Marketing EMEA at Allergan. "Our software suite and products are ideally suited to the needs of large, multi-national pharmaceutical companies who want to treat their customers as indivi
4/25/13 - Aptalis Chooses TransPerfect's Trial Interactive Technology as Its Pharmacovigilance System Master File Solution [Professional Services Close - Up]
TransPerfect, a provider of solutions for global development and commercialization of products to the life sciences industry, announced that Aptalis Pharma has implemented Trial Interactive as its global pharmacovigilance system master file solution. "We were aware of the European Medicines Agency's impending guidance that would require all produc
4/25/13 - Aptalis Taps TransPerfect's Trial Interactive Technology as Its Pharmacovigilance System Master File (PSMF) Solution [Health & Beauty Close - Up]
TransPerfect, a provider of solutions for global development and commercialization of products to the life sciences industry, announced that Aptalis Pharma has implemented Trial Interactive as its global pharmacovigilance system master file solution. "We were aware of the European Medicines Agency's impending guidance that would require all produc
4/25/13 - Aptalis Taps TransPerfect's Trial Interactive Technology as Its Pharmacovigilance System Master File Solution [Manufacturing Close - Up]
TransPerfect, a provider of solutions for global development and commercialization of products to the life sciences industry, announced that Aptalis Pharma has implemented Trial Interactive as its global pharmacovigilance system master file solution. "We were aware of the European Medicines Agency's impending guidance that would require all produc
4/25/13 - ARCA biopharma and Medtronic Partner on Atrial Fibrillation Clinical Trial for Gencaro [Health & Beauty Close - Up]
ARCA biopharma, Inc., a biopharmaceutical company, announced that it has entered into an agreement with Medtronic, Inc., a company focused on medical technologies, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro. Under the collaboration, ARCA plans, with the support of Medtronic, to cond
4/25/13 - Atlantic Information Services Adds Four Reports to Recently Launched White Paper? Feature on AISHealth.com
Atlantic Information Services, Inc. has added four new reports to the recently launched White Papers, Studies and Surveys? feature on AISHealth.com. 2. Meeting the Nation's Primary Care Needs: Current and Prospective Roles of Doctors of Chiropractic and Naturopathic Medicine, Practitioners of Acupuncture and Oriental Medicine, and Direct-En
4/25/13 - CBO: Key to Innovation is Making it a National Priority
To spur innovation in biopharma and other industries, Congress must make it a national priority, according to the Congressional Budget Office. Speaking this week at the National Bureau of Economic Research conference on innovation policy, Elmendorf outlined a number of possible policy approaches to once again promote innovation, ranging from increa
4/25/13 - CEL-SCI Updates Phase III Clinical Trial Progress [Health & Beauty Close - Up]
CEL-SCI Corp. has provided an update on the Phase III Clinical Trial of its investigational drug Multikine for the treatment of head and neck cancer. To date, the study has enrolled 117 patients and has been conducted at 39 sites in 8 countries, including three centers in Israel where CEL-SCI's partner Teva Pharmaceuticals has the marketing rights,
4/25/13 - Clinic Roundup
?AcelRx Pharmaceuticals Inc., of Redwood City, Calif., reported that its Phase II study of sublingual sufentanil NanoTab for acute pain, ARX-04, met its primary endpoint of significantly greater pain reduction than placebo. AcelRx will present the results to the U.S. Army Medical Research and Materiel Command, which funded the study, and plans to
4/25/13 - Concert Pharmaceuticals to Present at Annual Needham Healthcare Conference [Health & Beauty Close - Up]
Concert Pharmaceuticals, Inc. has announced that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, at 3 p.m. ET. The conference will be held April 30- May 1, at The Westin New York Grand Central Hotel. Concert Pharmaceuticals is a clinical stage b
4/25/13 - Cyberpills are bad for your health ; ONLINE MEDICINES CAN BE FAKE OR DANGEROUS WARNING DAILY Mirror INVESTIGATES [Ulster Region] [Mirror (UK)]
TENS of thousands of Britons dice with death by going online to buy potentially lethal medicines and health products. Earlier this week we revealed how bulimic Leeds University medical student Sarah Houston died after taking outlawed weight- loss pills bought online. After the hearing, Sarah's father, Dr Geoff Houston, begged those peddling it on t
4/25/13 - Cyberpills are bad for your health ; ONLINE MEDICINES CAN BE FAKE OR DANGEROUSwarning [Edition 2] [Mirror (UK)]
TENS of thousands of Britons dice with death by going online to buy potentially lethal medicines and health products. Earlier this week we revealed how bulimic Leeds University medical student Sarah Houston died after taking DNP capsules bought on the internet. After the hearing, Sarah's father, Dr Geoff Houston, begged those peddling it on the net
4/25/13 - Cyberpills are bad for your health ; ONLINE MEDICINES CAN BE FAKE OR DANGEROUSwarning [Mirror (UK)]
TENS of thousands of Britons dice with death by going online to buy potentially lethal medicines and health products. Earlier this week we revealed how bulimic Leeds University medical student Sarah Houston died after taking outlawed weight- loss pills bought online. After the hearing, Sarah's father, Dr Geoff Houston, begged those peddling it on t
4/25/13 - CytRx Reaches Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma [Health & Beauty Close - Up]
CytRx Corp., a biopharmaceutical research and development company specializing in oncology, said that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refract
4/25/13 - Denver Plastic Surgeon, Dr. Philippe A. Capraro Completes Certification for New FDA Approved Breast Implant
Allergan, Inc. has recently received approval from the U.S. Food and Drug Administration to market Natrelle 410, a Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant. We have been waiting years for this implant,? said Denver plastic surgeon, Dr. Capraro has served the Denver community.
4/25/13 - Don't Get Jack3d: What Attorney Jason Waechter Wants You to Know About Dietary Supplements.
In a news release in April 2012, the FDA issued warning letters to 11 companies asking them to stop using DMAA in their products, and remove any products containing DMAA from store shelves. It has been reported that USP Labs, who manufacture Jack3d, was the last company to comply with this request. A group of plaintiffs who are claiming that Jack3d
4/25/13 - Drug Companies Pay To Delay Cost Effective Generic Drugs; The Canadian Pharmacy States, "American Consumers Can Do Something About This"
On March 25th 2013 the U.S. Supreme Court heard arguments in the Federal Trade Commission v. The same report claims "A hypothetical consumer paying $300 per month for a brand-name drug, instead of a generic price as low as $30 per month, could pay as much as $270 per month more for prescription drugs. In the U.K. the British Office of Fair Trading
4/25/13 - Durham's Tranzyme to move HQ in merger with California company [The Herald-Sun, Durham, N.C.]
Tranzyme Inc.' s board has been looking into the possible sale, merger or other business combination for the company following the discontinued development of both of its two clinical-stage drug candidates. The merger with Ocera is expected to close in the third quarter, subject to approval by the majority of Tranzyme shareholders and other closing
4/25/13 - Elekta Receives U.S. FDA 510k Clearance Following Launch of New Versa HD Radiation Therapy System for Cancer Treatment
Elekta recently received 510 clearance from the U.S. Food and Drug Administration, allowing the company to begin shipping and installation of all components of the Versa HD? system within the United States. Featuring high precision beam shaping and tumor targeting, and capable of delivering radiation doses three times faster than previous Elekta
4/25/13 - Evaluate: Worldwide Orphan Drug Market to Grow to $127 Billion by 2018 [Health & Beauty Close - Up]
The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the new 2013 Orphan Drug Report from Evaluate. "Pharma has traditionally been focused on developing drugs for large disease populations," said Anthony Raeside, Evaluate's Head of Research.
4/25/13 - FDA Approves Duchesnay USA's Diclegis for Treatment of Nausea and Vomiting of Pregnancy NVP
It is the only FDA- approved treatment for NVP, more commonly known as morning sickness, in more than 30 years. "The FDA approval of Diclegis provides an important new treatment to the millions of women suffering from nausea and vomiting of pregnancy, and fills a 30 year void in the treatment of NVP," said Gilbert Godin, Chief Executive Officer, D
4/25/13 - Gavi-Bio E tie-up shrinks vaccine price [DNA : Daily News & Analysis (India)]
Hyderabad: Vaccine firm Biological E has stepped into the Big Pharma territory with its agreement with the Gavi Alliance for supply of' pentavalent vaccine'. Gavi used to procure the shots from Johnson& Johnson's Crucell, GlaxoSmithKline and LG Life Sciences. Unicef managed the tendering that led to vaccine supply deals with Biological E, Crucell,
4/25/13 - Glaxo may sell older drug brands [The Philadelphia Inquirer]
April 25 After reporting lower quarterly profits, drugmaker GlaxoSmithKline said Wednesday that it would reorganize its pharmaceutical divisions, with the possibility of someday selling older, "established" brands that it rarely promotes. Glaxo is based in London, but has about 1,300 employees in Philadelphia's Navy Yard and more in other facilit
4/25/13 - House Energy and Commerce Subcommittee on Health Hearing
My name is Walter Berghahn and I am the Executive Director of the Healthcare Compliance Packaging Council, a trade association dedicated to improving medication adherence and patient safety in the US pharmaceutical supply chain through broad adoption of innovative packaging technology. That being said, the membership of HCPC has been supportive of
4/25/13 - ImageIQ and IMARC Research Ink Co-Marketing Pact [Health & Beauty Close - Up]
ImageIQ, an imaging contract research organization and IMARC Research, a CRO offering monitoring, auditing and training services, have announced a partnership that will strengthen the abilities of both organization's clients to manage the complexities of imaging within clinical trials, and to enhance FDA approvals by ensuring that scientific data i
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2013 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Pharmacological Management of Diabetic Peripheral Neuropathy
This lesson is supported by:
Texas A&M Health Science Center Coastal Bend Health Education Center

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415